Hospital Universitario Virgen del Rocío -ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2023

  1. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients

    Medicina (Kaunas, Lithuania), Vol. 59, Núm. 8

2020

  1. Comparative study between two european inception cohorts of patients with early systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 925-932

2019

  1. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics

    Translational Psychiatry, Vol. 9, Núm. 1

2018

  1. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort

    Lupus, Vol. 27, Núm. 14, pp. 2253-2261

2017

  1. Características clínicas al diagnóstico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES

    Revista Clinica Espanola, Vol. 217, Núm. 1, pp. 7-14

2016

  1. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  3. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2012

  1. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

    Autoimmunity Reviews, Vol. 11, Núm. 5, pp. 357-364

  2. Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox.

    Current pharmaceutical design, Vol. 18, Núm. 32, pp. 5156-5164

2011

  1. Biologics use in SLE in 23 Centers - Data from the International Registry for Biologics In SLE (IRBIS)

    ARTHRITIS AND RHEUMATISM

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476